Lv21
110 积分 2022-04-24 加入
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
5小时前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
7小时前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
2天前
已完结
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
6天前
已完结
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)
6天前
已完结
Cutaneous T-cell Lymphoma
7天前
已完结
Cutaneous T-Cell Lymphoma: Epidemiology, Etiology, and Classification
7天前
已完结
Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics
1个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2个月前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
3个月前
已完结
皖公网安备34019202002308
